Management of early stage breast cancer: Interventions and their effectiveness

Disease Management and Health Outcomes

Volumn 2, Issue 6, 1997, Pages 270-280

  Dees, Elizabeth Claire ^a,b   Davidson, Nancy E ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344625058     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199702060-00002     Document Type: Article

References (48)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1997. CA Cancer J Clin 1997; 47: 5-27
2. Harris JR, Lippman ME, Veronesi U, et al. Breast cancer. N Engl J Med 1993; 327: 319-28, 390-8, 473-80
3. Garber JE, Smith BL. Management of the high-risk and the concerned patient. In: Harris JR, Lippman ME, editors. Diseases of the breast. Philadelphia: Lippincott-Raven, 1996
4. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71
5. Easton DF, Ford D, Bishop DT, et al. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995; 56: 265-71
6. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11: 198-200
7. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer. JAMA 1995; 273 (7): 577-85
8. Fitzgerald MG, MacDonald DJ, Krainer M, et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334: 143-9
9. Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996; 334: 137-42
10. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibiltiy gene BRCA2. Nature 1995; 378: 789-92
11. Wooster R, Neuhausen SL, Mangion J, et al. Localisation of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 285: 2088-90
12. Weber BL, Garbcr JE. Familial breast cancer: recent advances. In: Harris JR, Lippman ME, editors. Diseases of the breast [updates vol. 1]. Philadelphia: Lippincott-Raven, 1997
13. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and their risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93
14. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274 (2): 137-42
15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiologic studies. Lancet 1996; 347: 1713-27
16. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-5, 71-85
17. Veronesi U, De Palo G, Costa A, et al. Chemoprevention of breast cancer with retinoids. Monogr Natl Cancer Inst 1992; 12: 93-7
18. American Joint Committee on Cancer. In: Beahrs O, Hensen D, Hutter R, et al., editors. Manual for staging of cancer. Philadelphia: JB Lippincott, 1992: 149
19. Carter CL, Allen C, Henson D, et al. Relation of tumor size, lymph node status, an survival in 24740 breast cancer cases. Cancer 1989; 63: 181-7
20. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practices of oncology. 4th ed. Philadelphia, JB Lippincott, 1993: 1644
21. McGuire WL. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978; 5: 428
22. Fisher B, Montague E, Redmond C, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. Cancer 1977; 39: 2827-39
23. Morrow M, Harris J, Schnitt SJ. Local control following breast-conserving surgery for invasive cancer: results of clinical trials. J Natl Cancer Inst 1995; 87: 1669-73
24. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333: 1456-61
25. Fisher B, Redmond C, Fisher E, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674-81
26. Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15: 2345-50
27. Early Breast Cancer Trialists Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348: 1189-96
28. Glick JH, Gelber RD, Goldhirsch A, et al. Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst 1992; 84 (19); 1479-85
29. Goldhirsch A, Wood WC, Senn HJ, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1995; 87 (19): 1441-5
30. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2 (11): 1281-8
31. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330 (18): 1253-9
32. Fisher B, Anderson S, Wickerham L, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from NSABPB-22. J Clin Oncol 1997; 15: 1858-69
33. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9
34. Fisher B, Dignam J, Decillis A, et al. The worth of chemotherapy and tamoxifen over TAM alone in node-negative patients with estrogen receptor-positive invasive breast cancer: first results from NSABP B-20 [abstract]. Proc Am Soc Clin Oncol 1997; 16: 1a
35. Albain K, Green S, Osborne C, et al. Tamoxifen (T) versus cyclophosphamide, Adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor (+), node (+) breast cancer: a Southwest Oncology Group phase III intergroup trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 128a
36. Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334: 1356-61
37. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993; 11 (4): 771-6
38. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991; 324: 160-8
39. Desch CE, Hillner BE, Smith TJ. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993; 11: 777
40. ASCO Breast Cancer Surveillance Expert Panel. Recommended breast cancer surveillance guidelines. J Clin Oncol 1997; 15: 2149-56
41. Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745-51
42. Shapiro C, Recht A. Late effects of adjuvant therapy for breast cancer. Monogr Natl Cancer Inst 1994; 16: 101-12
43. DeCillis A, Anderson S, Bryant J, et al. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on NSABP B-25: an update [abstract]. Proc Am Soc Clin Oncol 1997; 16: 130a
44. Rutqvist LE. Long-term toxicity of tamoxifen. Recent Results Cancer Res 1993; 127: 257-66
45. Forbes JF. Long-term effects of adjuvant chemotherapy in breast cancer. Acta Oncol 1992; 31 (2): 243-50
46. Reichman BS, Green KB. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. Monogr Natl Cancer Inst 1994; 16: 125-9
47. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-29
48. Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors. JAMA 1994; 272 (7): 540-5